Biotech | November 26, 2025
Novartis scores FDA nod for game-changing SMA treatment
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)
Solventum aims to accelerate innovation in acute wound care, expand its market reach, and deliver enhanced solutions for patients, clinicians, and shareholders
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
The proposed transaction will be effected as a share swap
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
The company will soon be launching a new portfolio of products in this segment
The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases
Millions of stroke survivors across the world may soon have a new defense
Subscribe To Our Newsletter & Stay Updated
